RxDoctor Payments DataLook up a doctor →

Robert Balsiger, DO

Neurology · Las Vegas, NVNPI 1083935811

Payments from drug & device makers

$150,206in general payments, 2019–2025

Across 844 payments — averaging $177.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ipsen Pharma SAS$75K
  • Teva Pharmaceuticals USA, Inc.$58K
  • Novo Nordisk AS$5K
  • AbbVie$4K
  • Novartis$1K
  • Pfizer$884
  • plus $6K from 54 others

What the payments were for

  • Speaking & faculty fees$681%
  • Food & beverage$13,10698%
  • Education$2532%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Ipsen Pharma SAS49$74,802
Teva Pharmaceuticals USA, Inc.144$57,600
Novo Nordisk AS2$4,838
AbbVie(2 entities)208$4,388
Novartis90$1,401
Pfizer54$884
Amgen(2 entities)33$734
UCB, Inc.21$472
Genentech USA, Inc.27$356
AstraZeneca(2 entities)15$310
EMD Serono, Inc.11$280
Abbott5$263
Biohaven Pharmaceutical Holding Company Ltd.15$228
Sunovion Pharmaceuticals Inc.13$191
Acclarent, Inc3$187
Acadia Pharmaceuticals Inc10$184
Argenx US, Inc.11$177
MDD US Operations, LLC9$175
Integra Lifesciences Corporation1$174
Lundbeck LLC8$164
Sanofi7$153
Bristol Myers Squibb5$152
SK Life Science, Inc.6$119
Neurocrine Biosciences, Inc.5$115
Livanova USA, Inc.3$104
Ipsen Biopharmaceuticals, Inc5$102
Boston Scientific1$100
Biohaven Pharmaceuticals, Inc.4$97
Regeneron Healthcare Solutions, Inc.1$96
Takeda Pharmaceuticals U.S.A., Inc.4$90
Biogen4$74
Octapharma USA, Inc.5$74
Johnson & Johnson(2 entities)4$70
Acorda Therapeutics, Inc5$68
Mallinckrodt Enterprises LLC3$64
CSL Behring3$56
Mallinckrodt Hospital Products Inc.3$55
Aucta Pharmaceuticals, Inc.5$52
Catalyst Pharmaceuticals, Inc.3$50
Upsher-smith Laboratories LLC3$50
Zyla Life Sciences, Inc.4$49
Avanir Pharmaceuticals, Inc.3$48
Otsuka America Pharmaceutical, Inc.2$46
ANI Pharmaceuticals, Inc.2$44
Neuropace, Inc.1$41
Tanabe Pharma America, Inc.2$35
Sanofi-aventis U.S. LLC2$32
E.r. Squibb & Sons, L.L.C.2$29
Grifols USA, LLC2$29
Aquestive Therapeutics, Inc.1$26
Greenwich Biosciences, Inc.1$26
Alnylam Pharmaceuticals Inc.1$25
Lilly USA, LLC1$24
Harmony Biosciences LLC1$23
Assertio Therapeutics, Inc.2$22
Shire North American Group Inc1$22
Philips North America LLC1$20
Impel Pharmaceuticals Inc.1$20
Merz North America, Inc.1$19
Kyowa Kirin, Inc.1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$150,206 in reported general payments places this provider in the 85th percentile of 145 neurology providers in Nevada.

See all neurology providers in Nevada

Medicare billing

Part B allowed, 2024
$1,883,737
Medicare patients
1,134
Services billed
15,050

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5032$819,303
OctagamImmun Globg(Igg)/Malt/Iga Ov5034$308,778
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5026$247,425
BotoxOnabotulinumtoxina124$223,575
Rebif RebidoseInterferon Beta-1a/Albumin14$144,914
Avonex Pen (4 Pack)Interferon Beta-1a12$115,184
UbrelvyUbrogepant55$94,514
Nurtec OdtRimegepant Sulfate23$39,196
Emgality PenGalcanezumab-Gnlm15$10,040
Lacosamide74$5,537
Pyridostigmine Bromide24$3,078
Pregabalin132$2,987
Levetiracetam150$2,680
Gabapentin207$1,639
Donepezil Hcl134$982

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringPrivigen$56$819,30332 claims
PfizerOctagam, Nurtec Odt$884$347,97457 claims
AbbVieBotox, Ubrelvy$4,388$318,089179 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$90$247,42526 claims
Upsher-smith Laboratories LLCTopiramate$50$44751 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 145 neurology providers in Nevada.

Other neurology in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →